Inclusion Criteria:

Newly diagnosed stage I to III breast cancer and carcinoma in situ (including lobular carcinoma in situ [LCIS] and ductal carcinoma in situ [DCIS])
Breast surgery (lumpectomy or mastectomy) is planned for at least 7 days from the day of enrollment
Ability to understand and the willingness to sign an Institutional Review Board (IRB)-approved written informed consent document
Tumor measures at least 1 centimeter on imaging or physical exam
Exclusion Criteria:

Use of any corticosteroid or nonsteroidal anti-inflammatory drug (NSAID) for 2 weeks prior to study enrollment
Any patient with surgery scheduled < 7days after biopsy
Patients who are unable to refrain from the use of any NSAID or full-dose acetylsalicylic acid (ASA)-containing NSAID between biopsy and surgery
Patients who will receive neoadjuvant chemotherapy are not eligible
Patients who are currently taking omega-3 fatty acids, as they are unable to be randomized to placebo
Patients who have previously taken omega-3 fatty acid within 1 month prior to study enrollment
Patients with an allergy or known hypersensitivity to fish